Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA in cervical dystonia
NCT03608397Phase 3Completed
- Sponsor
- Revance Therapeutics
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of daxibotulinumtoxinA in cervical dystonia (CD), sponsored by Revance Therapeutics. Started Jun 2018; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT03608397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608397.